Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study.
Saved in:
| Title: | Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study. |
|---|---|
| Authors: | Nasrallah HA; University of Cincinnati College of Medicine, 260 Stetson Street, Suite 3200, Cincinnati, OH, 45219, USA. henry.nasrallah@uc.edu., Weiden PJ; Alkermes, Inc., Waltham, MA, USA., Walling DP; CNS Network, LLC, Garden Grove, CA, USA., Du Y; Alkermes, Inc., Waltham, MA, USA., Yao B; Alkermes, Inc., Waltham, MA, USA., Yagoda S; Alkermes, Inc., Waltham, MA, USA., Claxton A; Alkermes, Inc., Waltham, MA, USA. |
| Source: | BMC psychiatry [BMC Psychiatry] 2021 Oct 08; Vol. 21 (1), pp. 492. Date of Electronic Publication: 2021 Oct 08. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100968559 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-244X (Electronic) Linking ISSN: 1471244X NLM ISO Abbreviation: BMC Psychiatry Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1471-244X |
|---|---|
| DOI: | 10.1186/s12888-021-03420-x |
